Re: "reduced risk of lung cancer with metformin therapy in diabetic patients: A systematic review and meta-analysis"

American Journal of Epidemiology

Volumn 180, Issue 12, 2014, Pages 1216-1217

  Schmedt, Niklas ^a   Azoulay, Laurent ^b,c   Hense, Sabrina ^a  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CANCER INCIDENCE; CANCER PROGNOSIS; DIABETIC PATIENT; DRUG EXPOSURE; HIGH RISK PATIENT; HUMAN; LETTER; LUNG CANCER; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); DIABETES MELLITUS, TYPE 2; LUNG NEOPLASMS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; METFORMIN;

EID: 84922345428     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu311     Document Type: Letter

References (10)

1. Zhang Z-J, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol. 2014;180(1): 11-14.
2. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665-2673.
3. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012;12:410.
4. Hsieh MC, Lee TC, Cheng SM, et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782.
5. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9): 1620-1625.
6. Smiechowski BB, Azoulay L, Yin H, et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36(1):124-129.
7. Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34(4):923-929.
8. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012; 35(1):119-124.
9. Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37(9): 2522-2532.
10. Suissa S, Azoulay L. Metformin and cancer: mounting evidence against an association. Diabetes Care. 2014; 37(7):1786-1788.